Jinling Pharmaceutical Co Ltd

Jinling Pharmaceutical Corporation Limited announced that phloroglucinol orally disintegrating tablets, jointly developed with its related party Nanjing Adicaiteng Biomedical Limited Liability Company, have been approved by the National Medical Products Administration and obtained a drug registration certificate. The specification is 80 milligrams, and the registration classification is Category 3 chemical drug. The marketing authorization holder for the drug is Adicaiteng, and production is the responsibility of Nanjing Jinling Pharmaceutical Factory under Jinling Pharmaceutical. The project was reviewed and approved by the board of directors in August 2023 and accepted in October 2024. The company stated that this approval will help improve its product structure, but subsequent production and sales arrangements have not yet been agreed with Adicaiteng under a specific agreement, and there is uncertainty. It reminded investors to pay attention to risks.

Jinling Pharmaceutical released its 2026 interim report, with total operating revenue of 1.584 billion yuan and net profit attributable to the parent of 50.3825 million yuan, an increase of 2.0489 million yuan compared with the same period last year, up 4.24% year-on-year. Net cash inflow from operating activities was 247 million yuan, up 1461.39% year-on-year. The company's asset-liability ratio was 19.64%, gross margin was 22.38%, rising for six consecutive quarters, and ROE was 1.34%. Inventory turnover ranked first among peers, and the number of shareholders was 39,300.

Jinling Pharmaceutical released its 2026 half-year report, showing first-half net profit attributable to the parent of 50.38 million yuan, up 4.2% year on year. Operating revenue was 1.584 billion yuan, down 1.04% year on year. Net profit attributable to the parent after deducting non-recurring items was 48.91 million yuan, up 37.7% year on year. Net operating cash flow was 247 million yuan, up 1,461.4% year on year. Earnings per share were 0.081 yuan. In the second quarter, operating revenue was 816 million yuan, up 3.1% year on year. Net profit attributable to the parent was 22.38 million yuan, down 11.7% year on year. Net profit attributable to the parent after deducting non-recurring items was 29.65 million yuan, up 96.7% year on year. As of the end of the second quarter, total assets were 5.992 billion yuan, down 0.2% from the end of the previous year. Net assets attributable to the parent were 3.766 billion yuan, down 0.3% from the end of the previous year. The company said its operating business did not undergo major changes during the reporting period. Its main businesses cover pharmaceutical and medical device manufacturing, medical rehabilitation and elderly care services, and other areas. Core products form a multi-category coordinated development matrix, and the medical rehabilitation and elderly care segment maintained stable operations.

Jinling Pharmaceutical announced that the drug registration and marketing authorization application for Carboxymaltose Iron Injection from its branch, Fuzhou Meifeng Pharmaceutical Factory, has been accepted by the National Medical Products Administration. This drug is a third-generation intravenous iron agent used for treating iron deficiency anemia. Currently, only the original imported product is available on the domestic market. If approved, it will enrich the company's product pipeline and strengthen its competitive advantage in the iron supplement field.

Jinling Pharmaceutical has added two products, compound sulfamethoxazole injection and cefixime granules, to the National Essential Medicines List 2026 edition, which takes effect on September 1, 2026. Existing products such as ferrous succinate tablets and Mailuoning injection remain on the list, with no products removed. The company stated that this inclusion will help expand coverage of the relevant products in the primary healthcare market and have a positive impact on future market expansion. In the first quarter of 2026, Jinling Pharmaceutical achieved revenue of 769 million yuan and net profit attributable to the parent of 28 million yuan.